Most importantly, advanced NSCLC patients who harbor epidermal growth factor receptor (EGFR) mutations, which were found in about half of the advanced lung adenocarcinoma cases in Asians, can be treated with EGFR-tyrosine kinase inhibitor (TKI) [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.